Zuberbier T., Abdul Latiff A.H., Abuzakouk M., et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria // Allergy. 2022. Vol. 77, N 3. P. 734–766. doi: 10.1111/all.15090.
DOI: 10.1111/all.15090
Аллергология. Федеральные клинические рекомендации / под ред. Р.М. Хаитова, Н.И. Ильиной. Москва: Фармарус Принт Медиа, 2014. 126 с.
Moestrup K., Ghazanfar M.N., Thomsen S.F. Patient-reported outcomes (PROs) in chronic urticaria // Int J Dermatol. 2017. Vol. 56, N 12. P. 1342–1348. doi: 10.1111/ijd.13668.
DOI: 10.1111/ijd.13668
Maurer M., Weller K., Bindslev-Jensen C., et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report // Allergy. 2011. Vol. 66, N 3. P. 317–330. doi: 10.1111/j.1398-9995.2010.02496.x.
DOI: 10.1111/j.1398-9995.2010.02496.x
Gonçalo M., Gimenéz-Arnau A., Al-Ahmad M., et al. The global burden of chronic urticaria for the patient and society // Br J Dermatol. 2021. Vol. 184, N 2. P. 226–236. doi: 10.1111/bjd.19561.
DOI: 10.1111/bjd.19561
Weldon D.R. Quality of life in patients with urticaria // Allergy Asthma Proc. 2006. Vol. 27, N 2. P. 96–99.
O'Donnell B.F., Lawlor F., Simpson J., et al. The impact of chronic urticaria on the quality of life // Br J Dermatol. 1997. Vol. 136, N 2. P. 197–201.
Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria // Allergy. 2018. Vol. 73, N 7. P. 1393–1414. doi: 10.1111/all.13397.
DOI: 10.1111/all.13397
Grob J., Auquier P., Dreyfus I., Ortonne J. How to prescribe antihistamines for chronic idiopathic urticaria: Desloratadine daily vs PRN and quality of life // Allergy. 2009. Vol. 64. P. 605–612. doi: 10.1111/j.1398-9995.2008.01913.x.
DOI: 10.1111/j.1398-9995.2008.01913.x
Maurer M., Costa C., Gimenez Arnau A., et al. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study // Clin Exp Allergy. 2020. Vol. 50, N 10. P. 1166–1175. doi: 10.1111/cea.13716.
DOI: 10.1111/cea.13716
Guillen-Aguinaga S., Jauregui Presa I., Aguinaga-Ontoso E., et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: A systematic review and meta-analysis // Br J Dermatol. 2016. Vol. 175, N 6. P. 1153–1165. doi: 10.1111/bjd.14768.
DOI: 10.1111/bjd.14768
Wang L., Ke X., Kavati A., et al. Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria // Curr Med Res Opin. 2018. Vol. 34, N 1. P. 35–39. doi: 10.1080/03007995.2017.1395732.
DOI: 10.1080/03007995.2017.1395732
Zhao Z.T., Ji C.M., Yu W.J., et al. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials // J Allergy Clin Immunol. 2016. Vol. 137, N 6. P. 1742–1750.e4. doi: 10.1016/j.jaci.2015.12.1342.
DOI: 10.1016/j.jaci.2015.12.1342
Tharp M.D., Bernstein J.A., Kavati A., et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: A meta-analysis of "real-world" evidence // JAMA Dermatol. 2019. Vol. 155, N 1. P. 29–38. doi: 10.1001/jamadermatol.2018.3447.
DOI: 10.1001/jamadermatol.2018.3447
Fok J.S., Kolkhir P., Church M.K., Maurer M. Predictors of treatment response in chronic spontaneous urticaria // Allergy. 2021. Vol. 76, N 10. P. 2965–2981. doi: 10.1111/all.14757.
DOI: 10.1111/all.14757
Curto-Barredo L., Archilla L.R., Vives G.R., et al. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment // Acta Derm Venereol. 2018. Vol. 98, N 7. P. 641–647. doi: 10.2340/00015555-2941.
DOI: 10.2340/00015555-2941
Maurer M., Staubach P., Raap U., et al. H1-antihistamine-refractory chronic spontaneous urticaria: It's worse than we thought: First results of the multicenter real-life AWARE study // Clin Exp Allergy. 2017. Vol. 47, N 5. P. 684–692. doi: 10.1111/cea.12900.
DOI: 10.1111/cea.12900
Trinh H.K., Pham D.L., Ban G.Y., et al. Altered systemic adipokines in patients with chronic urticaria // Int Arch Allergy Immunol. 2016. Vol. 171, N 2. P. 102–110. doi: 10.1159/000452626.
DOI: 10.1159/000452626
Kolkhir P., Pogorelov D., Olisova O. CRP, D-dimer, fibrinogen and ESR as predictive markers of response to standard doses of levocetirizine in patients with chronic spontaneous urticaria // Eur Ann Allergy Clin Immunol. 2017. Vol. 49, N 4. P. 189–192. doi: 10.23822/eurannaci.1764-1489.05.
DOI: 10.23822/eurannaci.1764-1489.05
Sánchez Borges M., Tassinari S., Flores A. [Epidemiologic features in patients with antihistamine-resistant chronic urticaria. (In Spanish)] // Rev Alerg Mex. 2015. Vol. 62, N 4. P. 279–286.
Danilycheva I., Emelyanov A., Meshkova R., et al. Treating chronic urticaria refractory to H1-antihistamines in Russia: Data from the AWARE study // Postepy Dermatol Alergol. 2022. Vol. 39, N 3. P. 509–516. doi: 10.5114/ada.2022.117556.
DOI: 10.5114/ada.2022.117556
Ye Y.M., Jin H.J., Hwang E.K., et al. Co-existence of chronic urticaria and metabolic syndrome: Clinical implications // Acta Derm Venereol. 2013. Vol. 93, N 2. P. 156–160. doi: 10.2340/00015555-1443.
DOI: 10.2340/00015555-1443
Zbiciak-Nylec M., Wcisło-Dziadecka D., Kasprzyk M., et al. Overweight and obesity may play a role in the pathogenesis of chronic spontaneous urticaria // Clin Exp Dermatol. 2018. Vol. 43, N 5. P. 525–528. doi: 10.1111/ced.13368.
DOI: 10.1111/ced.13368
Lapi F., Cassano N., Pegoraro V., et al. Epidemiology of chronic spontaneous urticaria: Results from a nationwide, population-based study in Italy // Br J Dermatol. 2016. Vol. 174, N 5. P. 996–1004. doi: 10.1111/bjd.14470.
DOI: 10.1111/bjd.14470
Soria A., Du-Thanh A., Amsler E., et al.; French urticaria group (GUS) of French dermatological society. Obesity is not associated with severe chronic urticaria in a French cohort // J Eur Acad Dermatol Venereol. 2018. Vol. 32, N 6. P. e247–e249. doi: 10.1111/jdv.14767.
DOI: 10.1111/jdv.14767
Devaraj S., Rosenson R.S., Jialal I. Metabolic syndrome: An appraisal of the pro-inflammatory and procoagulant status // Endocrinol Metab Clin North Am. 2004. Vol. 33, N 2. P. 431–453. doi: 10.1016/j.ecl.2004.03.008.
DOI: 10.1016/j.ecl.2004.03.008
Neiman M., Hellström C., Just D., et al. Individual and stable autoantibody repertoires in healthy individuals // Autoimmunity. 2019. Vol. 52, N 1. P. 1–11. doi: 10.1080/08916934.2019.1581774.
DOI: 10.1080/08916934.2019.1581774
Tsigalou C., Vallianou N., Dalamaga M. Autoantibody production in obesity: Is there evidence for a link between obesity and autoimmunity? // Curr Obes Rep. 2020. Vol. 9, N 3. P. 245–254. doi: 10.1007/s13679-020-00397-8.
DOI: 10.1007/s13679-020-00397-8
Asero R., Cugno M. Biomarkers of chronic spontaneous urticaria and their clinical implications // Expert Rev Clin Immunol. 2021. Vol. 17, N 3. P. 247–254. doi: 10.1080/1744666X.2021.1882304.
DOI: 10.1080/1744666X.2021.1882304
Fang X., Li M., He C., et al. Plasma-Derived exosomes in chronic spontaneous urticaria induce the production of mediators by human mast cells // J Invest Dermatol. 2022. Vol. 142, N 11. P. 2998–3008.e5. doi: 10.1016/j.jid.2022.03.037.
DOI: 10.1016/j.jid.2022.03.037
Разина А.О., Руненко С.Д., Ачкасов Е.Е. Проблема ожирения: современные тенденции в России и в мире // Вестник Росс. акад. мед. наук. 2016. Т. 71, № 2. С. 154–159. doi: 10.15690/vramn655.
DOI: 10.15690/vramn655